New York, USA, April 25, 2023 (GLOBE NEWSWIRE) -- Glomerulonephritis Market Growing Significantly, Assesses DelveInsight | Otsuka Pharmaceutical, Chinook Therapeutics, Genentech, AstraZeneca, Novartis, Alexion, Vera Therapeutics, and Others Expected to Boost Glomerulonephritis Market
The glomerulonephritis market dynamics are expected to change in the coming years owing to the rising awareness of the disease and incremental healthcare spending worldwide. In addition, the anticipated launch of emerging therapies will also boost the glomerulonephritis market during the forecast period (2023–2032).
DelveInsight’s Glomerulonephritis Market Insights report includes a comprehensive understanding of current treatment practices, glomerulonephritis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Glomerulonephritis Market Report
- DelveInsight analysis shows that the glomerulonephritis market is expected to grow positively due to several underline factors during the study period (2019–2032).
- According to Wetmore et al. (2022), the period prevalence of glomerulonephritis with resultant death rates and end-stage renal disease in the United States are unknown. In this retrospective cohort study based on two US administrative datasets, the Medicare sample and the Optum Clinformatics Employer Group Health Plan (EGHP), the period prevalence per 100,000 individuals was 917 and 306 in Medicare and 52 and 70 in the health plan.
- Leading glomerulonephritis companies such as Otsuka Pharmaceutical Development & Commercialization, Inc., ACELYRIN Inc., Apellis Pharmaceuticals, Inc, Chinook Therapeutics, Inc, Visterra, Inc., HI-Bio, Genentech, Inc., RemeGen Co., Ltd., Vera Therapeutics, Inc, Novartis, Calliditas Therapeutics, Alpine Immune Sciences, Inc., Alexion, ChemoCentryx, Boehringer Ingelheim, Travere Therapeutics, Inc., Biocon Limited, River 3 Renal Corp., AstraZeneca, and others are developing novel glomerulonephritis drugs that can be available in the glomerulonephritis market in the coming years.
- Some of the key therapies for glomerulonephritis treatment include Sibeprenlimab, Pegcetacoplan, VB119, APL-2, Atrasentan, VIS649, Felzartamab, Obinutuzumab, Telitacicept, Atacicept, BION-1301, LNP023, Nefecon, Povetacicept, Ravulizumab, ALXN2050, CCX140-B, BI 764198, RE-021, Itolizumab, R3R01, Anifrolumab, and others.
- Several glomerulonephritis therapies are awaiting approval, while some therapies are in the advanced stages of development.
Discover which therapies are expected to grab the major glomerulonephritis market share @ Glomerulonephritis Market Report
Glomerulonephritis Overview
Glomerulonephritis, commonly known as nephritis or nephrotic syndrome, is a collection of disorders affecting the kidney’s glomeruli, which filter blood. Glomerulonephritis is a group of kidney illnesses marked by immune-mediated destruction to the basement membrane, mesangium, or capillary endothelium, resulting in hematuria, proteinuria, and azotemia. A variety of diseases can cause glomerulonephritis. Infections, autoimmune illnesses, vasculitis, sclerotic conditions, and other factors can all induce glomerulosclerosis. It may also be linked to cancers like gastric cancer, lung cancer, and chronic lymphocytic leukemia. The most common cause of glomerulonephritis worldwide is IgA nephropathy.
There are two forms of glomerulonephritis: acute and chronic. The acute type appears quickly, whereas the chronic form may appear slowly and without glomerulonephritis symptoms over time. It frequently results in total renal failure. The signs and glomerulonephritis symptoms differ depending on whether it is acute or chronic, as well as the reason. Hematuria, proteinuria, elevated blood pressure, edoema, frequent midnight urination, and highly bubbly or frothy urine are early indications and glomerulonephritis symptoms.
Glomerulonephritis Epidemiology Segmentation
The glomerulonephritis epidemiology section provides insights into the historical and current glomerulonephritis patient pool and forecasted trends for seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
The glomerulonephritis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Glomerulonephritis Prevalent Population
- Glomerulonephritis Diagnosed Prevalent Population
- Glomerulonephritis Gender-specific Prevalent Population
- Glomerulonephritis Treatable Cases
Download the report to understand which factors are driving glomerulonephritis epidemiology trends @ Glomerulonephritis Epidemiological Insights
Glomerulonephritis Treatment Market
Glomerulonephritis is a systemic condition that is mostly treated by treating the underlying cause. Primary glomerulonephritis is treated with supportive care as well as disease-modifying treatment. The outcome is primarily determined by timely intervention, which, if not performed, may result in a progressive sequence of events that causes glomerulonephritis to progress into chronic kidney disease (increasing the risk of concurrent development of cardiovascular disease), the sequence eventually culminating in end-stage renal disease (ESRD). Glomerulonephritis treatment is divided into two categories: specific management and non-specific management. As the condition progresses into chronicity, general management is implemented along the lines of chronic renal disease. Though there are no FDA-approved medications for glomerulonephritis treatment, numerous various therapies have been investigated to treat its distinct clinical manifestations.
Angiotensin-converting enzyme (ACE) inhibitors such as captopril, lisinopril, and perindopril, as well as angiotensin receptor blockers (ARBs) such as losartan, irbesartan, and valsartan c, assist in managing blood pressure. If a bacterial infection is still present when acute glomerulonephritis is identified. If glomerulonephritis is caused by malaria, antimalarial medications may be helpful. Some autoimmune illnesses that induce glomerulonephritis are treated with corticosteroids, immune suppressants, or both. High-dose corticosteroids, Rituximab, Cytotoxic agents (e.g., cyclophosphamide), and glucocorticoids are valuable in severe post-streptococcal cases glomerulonephritis), Plasma exchange (glomerular proliferative nephritis, pauci-immune glomerulonephritis - used temporarily till chemotherapy takes effect) are recommended depending upon the disease severity and the cause.
To know more about glomerulonephritis treatment, visit @ Glomerulonephritis Treatment Drugs
Key Glomerulonephritis Therapies and Companies
- Sibeprenlimab: Otsuka Pharmaceutical Development & Commercialization, Inc.
- Pegcetacoplan: Apellis Pharmaceuticals, Inc.
- VB119: ACELYRIN Inc.
- APL-2: Apellis Pharmaceuticals, Inc
- Atrasentan: Chinook Therapeutics, Inc
- VIS649: Visterra, Inc.
- Felzartamab: HI-Bio
- Obinutuzumab: Genentech, Inc.
- Telitacicept: RemeGen Co., Ltd.
- Atacicept: Vera Therapeutics, Inc
- BION-1301: Chinook Therapeutics, Inc.
- LNP023: Novartis
- Nefecon: Calliditas Therapeutics
- Povetacicept: Alpine Immune Sciences, Inc.
- Ravulizumab: Alexion
- ALXN2050: Alexion
- CCX140-B: ChemoCentryx
- BI 764198: Boehringer Ingelheim
- RE-021: Travere Therapeutics, Inc.
- Itolizumab: Biocon Limited
- R3R01: River 3 Renal Corp.
- Anifrolumab: AstraZeneca
Learn more about the FDA-approved drugs for glomerulonephritis @ Drugs for Glomerulonephritis Treatment
Glomerulonephritis Market Dynamics
In the coming years, the glomerulonephritis market is set to change due to the rising awareness of the disease and incremental healthcare spending worldwide; this would expand the glomerulonephritis market size to enable drug manufacturers to penetrate more into the glomerulonephritis market. A better understanding of glomerulonephritis pathogenesis will also contribute to developing novel therapeutics for glomerulonephritis. Moreover, several companies and academics are collaborating to examine difficulties and identify opportunities that could influence glomerulonephritis R&D. The drugs in development are focused on novel techniques for treating/improving disease conditions. In addition, the glomerulonephritis pipeline is highly robust; many possible therapies are being studied for glomerulonephritis treatment, and it is safe to assume that the therapeutic space will substantially impact the glomerulonephritis market throughout the forecast period.
However, certain factors may affect the growth of the glomerulonephritis market. The glomerulonephritis market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the glomerulonephritis market growth.
| Report Metrics | Details |
| Study Period | 2019–2032 |
| Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
| Base Year | 2019 |
| Key Glomerulonephritis Companies | Otsuka Pharmaceutical Development & Commercialization, Inc., ACELYRIN Inc., Apellis Pharmaceuticals, Inc, Chinook Therapeutics, Inc, Visterra, Inc., HI-Bio, Genentech, Inc., RemeGen Co., Ltd., Vera Therapeutics, Inc, Novartis, Calliditas Therapeutics, Alpine Immune Sciences, Inc., Alexion, ChemoCentryx, Boehringer Ingelheim, Travere Therapeutics, Inc., Biocon Limited, River 3 Renal Corp., AstraZeneca, and others |
| Key Glomerulonephritis Therapies | Sibeprenlimab, Pegcetacoplan, VB119, APL-2, Atrasentan, VIS649, Felzartamab, Obinutuzumab, Telitacicept, Atacicept, BION-1301, LNP023, Nefecon, Povetacicept, Ravulizumab, ALXN2050, CCX140-B, BI 764198, RE-021, Itolizumab, R3R01, Anifrolumab, and others |
Scope of the Glomerulonephritis Market Report
- Therapeutic Assessment: Glomerulonephritis current marketed and emerging therapies
- Glomerulonephritis Market Dynamics: Attribute Analysis of Emerging Glomerulonephritis Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Glomerulonephritis Market Access and Reimbursement
Discover more about glomerulonephritis drugs in development @ Glomerulonephritis Clinical Trials
Table of Contents
| 1. | Glomerulonephritis Market Key Insights |
| 2. | Glomerulonephritis Market Report Introduction |
| 3. | Glomerulonephritis Market Overview at a Glance |
| 4. | Glomerulonephritis Market Executive Summary |
| 5. | Disease Background and Overview |
| 6. | Glomerulonephritis Treatment and Management |
| 7. | Glomerulonephritis Epidemiology and Patient Population |
| 8. | Patient Journey |
| 9. | Glomerulonephritis Marketed Drugs |
| 10. | Glomerulonephritis Emerging Drugs |
| 11. | Seven Major Glomerulonephritis Market Analysis |
| 12. | Glomerulonephritis Market Outlook |
| 13. | Potential of Current and Emerging Therapies |
| 14. | KOL Views |
| 15. | Unmet Needs |
| 16. | SWOT Analysis |
| 17. | Appendix |
| 18. | DelveInsight Capabilities |
| 19. | Disclaimer |
| 20. | About DelveInsight |
Related Reports
Glomerulonephritis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key glomerulonephritis companies, including Vera Therapeutics, Inc, Novartis, Calliditas Therapeutics, Alpine Immune Sciences, Inc., Alexion, ChemoCentryx, among others.
Glomerulonephritis Epidemiology Forecast
Glomerulonephritis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted glomerulonephritis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
IgA Nephropathy Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key IgA nephropathy companies, including Omeros Corporation, Novartis Pharmaceuticals, Chinook Therapeutics, Visterra, Alnylam Pharmaceuticals, Vera Therapeutics, RemeGen, among others.
IgA Nephropathy Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key glomerulonephritis companies, including Clarity Pharmaceuticals Ltd, Eli Lilly and Company, Laboratorio Elea Phoenix S.A., PersonGen BioTherapeutics (Suzhou) Co., Ltd., among others.
IgA Nephropathy Epidemiology Forecast
IgA Nephropathy Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted IgA nephropathy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Other Trending Reports
Treatment Resistant Depression Market | Advanced Renal Cell Carcinoma Market | Glomerulonephritis Market | Centronuclear Myopathy Market | Head And Neck Squamous Cell Carcinoma Market | Acquired Immunodeficiency Syndrome Market | Acute Intermittent Porphyria Market | Neurovascular Devices Market | Defibrillators Market | Ventricular Hypertrophy Market | Urolithiasis Market | Alopecia Areata Market | Autonomic Dysfunction Market | Acute Ischemic Stroke Ais Market | Adenoid Cystic Carcinoma Market | Aspergillosis Market | Biliary Atresia Market | Biliary Tumor Market | Chronic Inducible Urticaria Market | Chronic Insomnia Market | Critical Limb Ischemia Market | Endometriosis Pain Market | Generalized Anxiety Disorder Gad Market | Hallux Valgus Market | Hemophilia B Market | Immunologic Deficiency Syndrome Market | Neuromodulation Devices Market | Neurovascular Thrombectomy Devices Market | Osteosarcoma Market | Pemphigus Vulgaris Market | Progressive Familial Intrahepatic Cholestasis Market | Pruritus Market | Radiation Toxicity Market | Pulmonary Hypertension Associated With Interstitial Lung Disease Market | Cluster Headaches Market | Foot And Ankle Devices Market | Intravenous Immunoglobulin Market | Bile Duct Neoplasm Market | Blood Glucose Monitoring Systems Market | Rett Syndrome Market | Tissue Heart Valves Market | Cardiac Biomarkers Testing Devices Market | Subscription Healthcare | Hepatorenal Syndrome Market | Central Venous Catheters Market | Continuous Renal Replacement Therapy Machines Market | Nonalcoholic Steatohepatitis Market | Necrotizing Enterocolitis Market | Cardiac Amyloidosis Market | Artificial Iris Market | Aortic Aneurysm Stent Grafts Market | Polypoidal Choroidal Vasculopathy Market | Adrenal Crisis Market | Hearing Implants Market | Image Guided Surgery Devices Market | Angioedema Market | Bladder Cancer Market
Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us on LinkedIn|Facebook|Twitter
